title: [Management of COPD according to severity by respiratory specialists in France].
abstract: BACKGROUND
  The diagnosis and treatment of chronic obstructive pulmonary disease (COPD) is suboptimal in many patients, which may impact on morbidity, mortality, use of healthcare resources and patients' overall quality of life.
  
  
  OBJECTIVE
  To describe the management of COPD by respiratory physicians from the French mainland according to severity.
  
  
  METHODS
  Observational cross-sectional survey performed in France in 2006-2007. 515 pulmonologists located throughout the national territory were involved and each of them had to recruit 5 patients with stable COPD.
  
  
  RESULTS
  The study included 2494 patients (mean age 67 years, 78% males), of whom nearly 50% had severe to very severe COPD (GOLD stage III-IV). At inclusion, 93.2% of patients were receiving pharmacological treatment, most often non-nebulised bronchodilators (91.2%) and/or inhaled corticosteroids (73.7%). Pulmonary rehabilitation was scheduled or had been performed within the last 2 years in 26.9% of patients. Investigations and treatments were more frequent when the disease was more severe, but there was considerable overlap between severity grades.
  
  
  CONCLUSIONS
  Differences in decisions about the investigation and treatment of COPD by pulmonologists can not be explained only by the severity of disease. Efforts must be made to identify other patient characteristics associated with these decisions, in order to help developing future recommendations.
authors: Service de Pneumologie et Réanimation, Hôpital de l'Hôtel Dieu, 1 place du Parvis de Notre-Dame, 75004 Paris. nicolas.roche@htd.aphp.fr
authors: N
authors: N
authors: Roche
authors: B
authors: B
authors: Delclaux
authors: Y
authors: Y
authors: Martinat
authors: C
authors: C
authors: Chouaid
authors: J-M
authors: JM
authors: Marcos
authors: H
authors: H
authors: Pégliasco
authors: B
authors: B
authors: Scherrer
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000368:Aged; D001993:Bronchodilator Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015897:Comorbidity; D003430:Cross-Sectional Studies; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005541:Forced Expiratory Volume; D005602:France; D019983:Guideline Adherence; D006801:Humans; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D011795:Surveys and Questionnaires; D014600:Utilization Review; D014797:Vital Capacity
chemical_list: D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents